Geron ($GERN) Misleading Rytelo Launch and Growth Projections Case

• $GERN investors filed a lawsuit against Geron for misleading shareholders about the commercial launch and expected growth of its drug, Rytelo (imetelstat).

• After reporting stalled sales growth and weak adoption on February 26, 2025, $GERN fell 32.07%.

• $GERN investors can join this case to stay updated on potential recovery.

Case Details:

On February 26, 2025, Geron ($GERN) announced its Q4 2024 financial results, revealing that sales of Rytelo had stagnated despite previous assurances of strong demand.

Geron admitted that Rytelo’s sales had stalled, with fewer new patients starting treatment than expected. Despite earlier claims that Rytelo would be widely adopted for lower-risk MDS, doctors were hesitant to prescribe it due to low awareness, strict monitoring requirements, and competition from other treatments.

The company had previously assured investors that demand would stay strong, citing FDA approval and expected use in first-line ESA-ineligible patients. However, most prescriptions came from later-line patients, not the broader market Geron had targeted.

When Geron finally acknowledged these issues, $GERN plummeted 32.07% in a single day.

Based on these events, $GERN investors filed a lawsuit against Geron, claiming the company:

• It misled investors about the strength of Rytelo’s launch and commercial adoption.

• It failed to disclose that most new prescriptions were in later-line settings rather than first-line ESA-ineligible patients.

• It downplayed challenges related to physician awareness, monitoring burdens, and competition.

Investors believe Geron knowingly misrepresented Rytelo’s commercial potential.